NCT02488382 is a Phase 1/Phase 2 clinical trial of Lonquek in Lymphoma, sponsored by Sheba Medical Center.

Who is sponsoring NCT02488382?

NCT02488382 is sponsored by Sheba Medical Center.

What drugs are being tested in NCT02488382?

Interventions in NCT02488382: Lonquek.

What condition does NCT02488382 study?

NCT02488382 studies Lymphoma, Multiple Myeloma.

Is NCT02488382 still recruiting?

NCT02488382 is currently status unknown. Last updated 16 October 2017.

Last reviewed 2017-10-16 · How we verify

NCT02488382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma

Status unknown Phase 1/Phase 2 Last updated 16 October 2017

What this trial tests

Phase 1/Phase 2 trial testing Lonquek in Lymphoma in 24 participants. Status unknown.

Timeline

1 July 2017

Primary endpoint
1 July 2018

1 July 2020

Quick facts

Lead sponsor	Sheba Medical Center
Phase	Phase 1/Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	1 July 2017
Primary completion	1 July 2018
Estimated completion	1 July 2020
Sites	1 location across Israel

Drugs / interventions tested

Lonquek — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →
Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Sheba Medical Center

Who can join

Adults 18 to 65, any sex, with Lymphoma or Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mobilisation success rate
Time frame: 4 weeks
Mobilisation success rate is defined as the mobilisation of a peripheral blood stem cell graft containing \>2x106 CD34+ cells/kg in ≤ 4 apheresis sessions.

Sponsor's own description

The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem cells for autologous stem cell transplantation in patients with lymphoma and multiple myeloma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.
Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, et al · · 2021 · cited 5× · PMID 34213732 · DOI 10.1007/s12185-021-03177-9

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other Sheba Medical Center trials

Trials by the same sponsor.

NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02488382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
Last refreshed: 16 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02488382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing